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Why Do We Need the Flu Shot Every Year?
There is a need for a new vaccine every year due to
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To this day, smallpox is the only disease confirmed to be
eradicated worldwide. This would not have been possible without the first widely utilized vaccine developed
nearly 200 years prior by Edward Jenner. Inspired by
Jenner’s methodology of using the cowpox virus to protect against smallpox in humans, vaccine innovations
and their significance to public health took off after Louis Pasteur’s discovery of the rabies vaccine in 1885.
Vaccines are perhaps the greatest immunological feat
to this day. So why are people still so averse to getting
vaccinated, especially for the flu? Encouraging people
to get their annual flu shot and persuading the public of
its effectiveness are two vital measures for preventing
flu-related hospitalizations and deaths.

significantly reduces flu-related hospitalizations and fatalities (Nichols, 2018). The effectiveness of the flu vaccine varies from year to year depending on how well the
projected vaccine antigen sequences matches the actual seasonal viral antigen. Although some years have
better predictions than others, the overall effectiveness
of the vaccine tends to be 40-60% (CDC).

Flu History
World War I played a significant role in the first influenza outbreak. The war brought the mass mobilization
of over 60 million soldiers with significantly different
backgrounds and immune systems to highly concentrated war zones in Europe. This, coupled with years
of unsanitary lifestyles, facilitated high transmission
rates leading to the H1N1 influenza pandemic outbreak
in 1918 (Matthews, 2014). Over 50 million people died
and many more were infected by the end of this pandemic. At the time, the only preventative measure that
was exercised was quarantine.
About twenty years later, the influenza A and B viruses
were isolated in the lab. Although vaccinations against
this virus have been in development since the 1930’s,
numerous clinical trials have debunked the effectiveness of the influenza vaccine for decades after the
1918 pandemic (National Vaccine Information Center).
A century after the first influenza outbreak, the CDC reported that the flu vaccine decreases the prevalence of
flu related illness, hospitalization, and death, especially
in young children and elderly people. Numerous studies have suggested that the trivalent influenza vaccine
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Waves of first influenza outbreak 1918 (Potter, 2008)

What is the Flu Virus?
The influenza virus is characterized by two envelope
proteins. Hemagglutinin (HA) is the protein that allows
the virus to attach to host cells, while neuraminidases
(NA) release the virus from the host cell (Morgridge).
There are sixteen known types of hemagglutinin and
nine known types of neuraminidase, which gives 144
different possible combinations of these proteins (Morgridge). Different viral strains contain distinct hemagglutinin and neuraminidase proteins, such as H1N1,
the most common influenza A known as the “swine flu.”
Influenza vaccines contain three to four of the most
common influenza strains, which are typically H1N1,
H2N2, H2N3, and influenza B. The flu vaccine tends to
be twice as effective in preventing H1N1 than H2N3 and
influenza B (Rondy et al., 2018). This is one reason why
the vaccine is not effective for everyone.

antigenic drift. The antibodies that your body produced
in response to last year’s flu shot are specific to the viral
antigens from that year’s version of the vaccine. When
a mutated version of that virus enters the body, these
antibodies are no longer able to evoke an immune response (Potter, 2008). Since the virus mutates slightly
each season, new vaccines with slightly different antigen combinations must be developed to recognize
the hemagglutinin and neuraminidase proteins of the
mutated virus. Once the vaccine is administered, your
innate immune system will create a cascade effect to
activate B-cells to produce antibodies. If you were to
contract the influenza virus, ideally your body would already have the necessary antibodies to fight the virus
and produce minimal flu-like symptoms. The vaccine
enables our bodies to combat the virus by generating
antibodies in advance. Within two weeks of vaccination,
the adaptive immune system should have generated
appropriate defenses against contracting the seasonal
strain of the flu (CDC).
How Do I Choose a Vaccine?
The two most conventional types of flu vaccinations are
egg based. These include the killed vaccine, taken as
an intramuscular shot or live attenuated nasal spray
vaccine (CDC). The killed vaccine involves injecting
a fertilized hen egg with the influenza virus and later
harvesting and purifying the viral fluid to acquire the inactivated viral antigen. The live attenuated vaccination
is a weakened version of four common strains of live
influenza viruses. This attenuated nasal spray is not
recommended for people over 50 or immunodeficient
recipients. Live attenuated vaccine is cold adapted, so
the virus cannot survive and replicate in the warm environment of the lungs and cause an infection. Although
vaccines are developed using viruses, the flu shot cannot cause the flu.
Innovations within the past five years include cell-based
and recombinant technology (Nation Vaccine Information Center). The inactivated cell-based flu shot is produced in a similar way to the egg-based killed vaccine,
but the viral antigen is extracted from a mammalian cell
culture rather than utilizing chicken eggs. The recombinant vaccine requires isolating a gene expressing viral
specific protein. Typically the gene encoding for HA is
injected into an insect virus, so it can be replicated within insect cells. This process is faster than other methods because the virus does not need to undergo an attenuation phase to grow in eggs or cell cultures (CDC).
Recent Trials for Vaccine Development

agglutinin and has the most promising immunological
success rate according to data acquired so far from the
clinical trials (Taylor, 2018). About a dozen more influenza universal vaccines, each founded upon slightly
modified approaches, are in the earlier stages of clinical trials. Increased public cooperation coupled with
advancements in biomedical vaccination technology
will hopefully lead to the stark decrease and eventual
eradication of influenza viruses.
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Since the first influenza outbreak 100 years ago, a universal flu vaccine may become available in the near future. BiondVax’s M-001 peptide vaccine has reached a
phase 3 clinical trial in Europe. Instead of targeting the
seasonally variable antigen surface of hemagglutinin
and neuraminidase proteins, M-001 targets nine highly conserved epitopes of the flu virus. These epitopes,
which are part of an antigen that are recognized by the
immune system, don’t change seasonally. So, ideally,
you would only need one universal flu shot that would
be effective for your lifetime. This approach allows for
protection against all strains of influenza virus. Getting
the universal vaccine in conjunction with the seasonal
vaccine stimulates antibody production against hemPage Design by Molly McCoy

